Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
| ▸ | ATXN2 | Q99700 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29731215 | 0.99 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL30057450 | 0.92 | MEN1 (0.53) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL9657187 | 0.87 | SMN1; SMN2 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL1709936 | 0.86 | MEN1 (0.59) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL29266964 | 0.84 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL56293 | 0.84 | OPRD1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL1709810 | 0.84 | MEN1 (0.58) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL6827246 | 0.84 | MEN1 (0.61) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL18132120 | 0.84 | MEN1 (0.51) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 | |
| SCHEMBL934263 | 0.84 | MEN1 (0.64) | MEN1KMT2ANPSR1SMN1; SMN2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727543-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024259345-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240336612-A1 | BRM Targeting Compounds And Associated Methods Of Use | PRELUDE THERAPEUTICS INCORPORATED | 2024-10-10 | — | — | US | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023287787-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2021064189-A2 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2021-04-08 | — | — | WO | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| EP-1119355-B1 | NAPHTHALENECARBOXAMIDES AS TACHYKININ RECEPTOR ANTAGONISTS | ASTRAZENECA AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| US-6500818-B1 | Naphthalenecarboxamides as tachykinin receptor antagonists | ASTRAZENECA AB (SE) | 2002-12-31 | — | — | US | disclosed |
| CN-1322134-A | Naphthalenecarboxamides as tachykinin receptor antagonists | ASTRA ZENECA N V (SE) | 2001-11-14 | — | — | CN | disclosed |
| EP-0231087-B1 | HEPTANOYL-GLU-ASP-ALA-AMINO ACID IMMUNOSTIMULANTS | PFIZER INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| US-4851388-A | Heptanoyl-glu-asp-ala-amino acid immunostimulants | PFIZER INC. (US) | 1989-07-25 | — | — | US | disclosed |
| EP-0231087-A2 | Heptanoyl-glu-asp-ala-amino acid immunostimulants | PFIZER INC. (US) | 1987-08-05 | — | — | EP | disclosed |
| WO-1987004440-A1 | HEPTANOYL-GLU-ASP-ALA-AMINO ACID IMMUNOSTIMULANTS | PFIZER INC. (US) | 1987-07-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336612-A1 | BRM Targeting Compounds And Associated Methods Of Use | ADRM1, BRDT, RBX1 | MEN1 3067/4885KMT2A 1311/4885NPSR1 4135/4885 |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | MEN1 2345/4885KMT2A 4780/4885NPSR1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.